End
1 :

Day 1:

1415:

Fundal height 37cm. Facial edema observed as well as +3 edema in the lower extremities.

Patellar reflex 3+, clonus negative. FHR 158/min with moderate variability with accelerations observed. Occasional mild contraction observed on EFM. Sterile vaginal examination performed. Cervix 1 cm dilated and 30% effaced. No vaginal bleeding or leakage of amniotic fluid observed. 1500:

Patellar reflexes 3+. Reports headache is worsening rates pain as an 8 on 0 to 10 pain scale

Day 2:

1500:

Fundal height 37cm. Facial edema observed as well as +2 edema in the lower extremities.

Patellar reflexes 4+, clonus present. FHR 120s with minimal variability. No accelerations observed. Rare contraction observed on electronic fetal monitor. No vaginal bleeding or leakage of amniotic fluid observed.

Day 1

1330:

Admit to antepartum unit for blood pressure monitoring Apply external

electronic fetal monitor (EFM)

Monitor BP and deep tendon reflexes every hour

Notify provider for systolic BP greater than 160 and/or diastolic BP greater than 110

Obtain CBCI BUN, Creatinine, PTL fibrinogen, and liver enzymes

Repeat lab work in 24 hr Notify provider if client's condition worsens or of changes in fetal status

1515:

Start a 4 g magnesium sulfate bolus and infuse over 20 min. After infusing the magnesium sulfate bolus, infuse magnesium sulfate at a rate of 2 g per hr.

1400:

Client received to unit_ BP readings in clinic were 156/90 mm Hg and 154/92 mm Hg_ Reported headache, heartburn, and edema in the hands for the last several days. Continues to report headache and epigastric pain. Rates pain with headache as a 4 on a 0 to 10 pain scale. EFM applied.

1430:

Lab drawn. Urine dipstick 2+ protein. FHR130s with moderate variability and accelerations present Occasional contraction observed on electronic fetal monitor Denies pain with contractions

1515:

Provider notified of changes in client's status and BP readings.

Day 2

1500:

Resting quietly with eyes closed_ Magnesium sulfate infusing intravenously at 2g/hr reports headache as a 2 on 0 to 10 pain scale_

Denies epigastric pain. Urine dipstick 2+ protein

Diagnostic tests

AST 250 U'L

ALT 213 IJ/L

ALP: 300 WL

T Bilirubin: 30 mg/dL

D. Bilirubin: 18mg/dL

Day 2:

AST113 IJ/LALT94 IJ/LALP:150 C.J/L

T Bilirubin: 18 mg/dL

D. Bilirubin: 1.2mg/dL


For each day 2 finding, click to specify whether the finding indicates that the client's condition has improved, has not changed, or has declined.


Options improved not changed declined
Liver function tests
Edema
Fetal heart rate and variability
Headache
Epigastric discomfort
Urine dipstick

Hint : 📉 Most signs improving, fetus declining.

Correct Answers

  • Liver function tests [ improved ]
  • Edema [ improved ]
  • Fetal heart rate and variability [ declined ]
  • Headache [ improved ]
  • Epigastric discomfort [ improved ]
  • Urine dipstick [ not changed ]

Rationale :

🔷 Liver function tests – Improved

🔷 Day 1 labs showed AST 250 U/L, ALT 213 U/L, and bilirubin 30 mg/dL, which are highly elevated, indicating hepatic involvement typical of severe preeclampsia or HELLP syndrome.

🔷 On Day 2, there is a notable decline in liver enzymes and bilirubin levels (AST 113 U/L, ALT 94 U/L, bilirubin 18 mg/dL), indicating improvement in hepatic function.

🔷 The downward trend in these values demonstrates that the client is responding to treatment, particularly magnesium sulfate therapy.

🔷 These lab improvements signal a reduction in systemic inflammation and hepatic strain.

🔶 Edema – Improved

🔶 On Day 1, the client had +3 lower extremity edema and facial edema, signs of fluid retention and vascular permeability due to preeclampsia.

🔶 On Day 2, lower extremity edema decreased to +2, though facial edema remained, indicating partial fluid status improvement.

🔶 This change implies reduced capillary leakage or improved vascular tone.

🔶 Though not completely resolved, the lesser degree of edema represents clinical improvement.

💠 Fetal heart rate and variability – Declined

💠 FHR on Day 1 was 158 bpm with moderate variability and accelerations, showing good fetal oxygenation.

💠 By Day 2, the FHR dropped to the 120s, with minimal variability and no accelerations, indicating possible fetal distress or CNS suppression from worsening maternal status or magnesium.

💠 These non-reassuring signs suggest decreased fetal well-being and warrant prompt evaluation.

💠 The decline in variability and acceleratory patterns represents a deterioration in fetal condition.

🔵 Headache – Improved

🔵 On Day 1, the client reported a severe headache (8/10), a neurological sign of worsening preeclampsia.

🔵 On Day 2, headache intensity decreased to 2/10, showing response to magnesium sulfate and CNS stabilization.

🔵 This change demonstrates reduced cerebral vasospasm or pressure.

🔵 The relief of this symptom reflects a positive neurological response to treatment.

🟣 Epigastric discomfort – Improved

🟣 Epigastric pain was reported on Day 1, a red flag for possible hepatic capsule distension or HELLP syndrome.

🟣 On Day 2, the client denied epigastric pain, showing reduction in liver irritation or swelling.

🟣 The symptom resolution suggests improvement in hepatic inflammation and reduced risk of hepatic rupture.

🟣 This marks clear symptomatic improvement in maternal condition.

⚫ Urine dipstick – Not changed

⚫ On both days, the urine dipstick showed 2+ protein, reflecting persistent proteinuria, a hallmark of preeclampsia.

⚫ The absence of change indicates that renal involvement remains ongoing despite improvement in other symptoms.

⚫ This suggests stable but unresolved kidney pathology, requiring continued monitoring.

⚫ No improvement in this marker implies persistent glomerular permeability.


Distractor Analysis :

Rationale for Incorrect Options to be Available Soon

QLexNursing Calculator Click & Drag ×
AC
(
)
CE
π
e
φ
τ
Inv
sin-1
cos-1
tan-1
log
ln
!
deg
√
x²
x³
^
7
8
9
÷
4
5
6
×
1
2
3
-
0
.
exp
+
Rnd
Ans
=